The Eversense 365 is a fully implantable CGM designed to last an entire year — eliminating the hassle of frequent sensor replacements. Developed by Senseonics and distributed by Ascensia, this next-gen device is catching attention for its unique approach to glucose monitoring.

Here’s how the implantable works: It uses a tiny sensor implanted under the skin that pairs with a removable, rechargeable transmitter worn on the surface. It sends real-time glucose data directly to your phone—including predictive alerts to help you stay ahead of highs and lows.

What’s new with Eversense 365? According to company leaders, this version brings major upgrades—from improved accuracy to a more comfortable transmitter design. Plus, the transmitter now supports the much more universal USB-C for charging. The company is also working on making the system compatible with insulin pumps—in fact, its first integration to automate insulin will be on the twiist AID system just released.

Challenges still remain. Insurance coverage isn’t always guaranteed, and the idea of an implant that still requires an external transmitter may deter some users. But our guests explain that the company is developing a sensor that doesn’t require an external transmitter.

We explore what’s next for the Eversense platform — highlighting the team’s vision for broader access, smarter tech, and an eventual implant that is self-powered.

If you’re as fascinated by innovation in diabetes care as I am, then Eversense is one for you to watch. If you're curious about how this CGM stacks up, or want to see where it's headed next, we dive deep into it in the latest podcast episode. Watch the full interview below or listen at the top of this page.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.